ValiRx (LSE:VAL) Market Cap : £4.43 Mil (As of Apr. 30, 2024)

View and export this data going back to 2000. Start your Free Trial

What is ValiRx Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). ValiRx's share price for the quarter that ended in Jun. 2023 was £0.0725. ValiRx's Shares Outstanding (EOP) for the quarter that ended in Jun. 2023 was 102.32 Mil. Therefore, ValiRx's market cap for the quarter that ended in Jun. 2023 was £7.42 Mil.

ValiRx's quarterly market cap increased from Jun. 2022 (£9.69 Mil) to Dec. 2022 (£12.62 Mil) but then declined from Dec. 2022 (£12.62 Mil) to Jun. 2023 (£7.42 Mil).

ValiRx's annual market cap increased from Dec. 2020 (£12.65 Mil) to Dec. 2021 (£23.58 Mil) but then declined from Dec. 2021 (£23.58 Mil) to Dec. 2022 (£12.62 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ValiRx's Enterprise Value for Today is £3.57 Mil.

ValiRx Market Cap Historical Data

The historical data trend for ValiRx's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Market Cap Chart

ValiRx Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Market Cap

Get a 7-Day Free Trial

4.94

1.60

12.65

23.58

12.62

ValiRx Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Market Cap	Get a 7-Day Free Trial															12.20	23.58	9.69	12.62	7.42

Competitive Comparison of ValiRx's Market Cap

For the Biotechnology subindustry, ValiRx's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ValiRx's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's Market Cap distribution charts can be found below:

* The bar in red indicates where ValiRx's Market Cap falls into.

ValiRx Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

ValiRx's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as

Market Cap (A: Dec. 2022 )	=	Share Price (A: Dec. 2022 )	*	Shares Outstanding (EOP) (A: Dec. 2022 )
	=	£0.14	*	90.1742
	=	£12.62

ValiRx's Market Cap for the quarter that ended in Jun. 2023 is calculated as

Market Cap (Q: Jun. 2023 )	=	Share Price (Q: Jun. 2023 )	*	Shares Outstanding (EOP) (Q: Jun. 2023 )
	=	£0.0725	*	102.32
	=	£7.42

ValiRx (LSE:VAL) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

ValiRx Market Cap Related Terms

Thank you for viewing the detailed overview of ValiRx's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx (LSE:VAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.